Early prediction of clinical and functional outcome in schizophrenia

European Neuropsychopharmacology

Volumn 23, Issue 8, 2013, Pages 842-851

  Agid, Ofer ^a   Siu, Cynthia O ^b   Pappadopulos, Elizabeth ^c   Vanderburg, Douglas ^c   Remington, Gary ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b One Palomino Ct   (United States)

^c PFIZER INC   (United States)

Author keywords

Benefit risk profile; Cognitive impairment; Early psychotic response; Global functioning; Predictive function; Weight gain

Indexed keywords

OLANZAPINE; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL INDICATOR; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT DURATION; WEIGHT CHANGE;

BENEFIT-RISK PROFILE; COGNITIVE IMPAIRMENT; EARLY PSYCHOTIC RESPONSE; GLOBAL FUNCTIONING; PREDICTIVE FUNCTION; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PATIENT DROPOUTS; PIPERAZINES; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; THIAZOLES; WEIGHT GAIN;

EID: 84881666249     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.10.005     Document Type: Article

References (54)

1. Aas I.H.M. Global Assessment of Functioning (GAF), properties and frontier of knowledge. Ann. Gen. Psychiatry 2010, 9:20. 10.1186/1744-859X-9-20.
2. Addington J., Addington D., Maticka-Tyndale E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr. Res. 1991, 4:123-134.
3. Adddington D.E.N., Pantelis C., Dineen M., et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder, an 8-week, double-blind, multicenter trial. J. Clin. Psychiatry 2004, 65:1624-1633.
4. Agid O., Kapur S., Arenovich T., Zipursky R.B. Delayed-onset hypothesis of antipsychotic action, a hypothesis tested and rejected. Arch. Gen. Psychiatry 2003, 60:1228-1235.
5. Agid O., Seeman P., Kapur S. The "delayed onset" of antipsychotic action-an idea whose time had come and gone. J. Psychiatry Neurosci. 2006, 31:93-100.
6. Agid O., Kapur S., Warrington L., Loebel A., Siu C. Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr. Res. 2008, 102:241-248.
7. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Capelleri J.C., Infante M.C., Weiden P.J. Antipsychotic induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999, 156:1686-1696.
8. Andreasen N.C., Carpenter W.T., Kane J.M., et al. Remission in schizophrenia, proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162:441-449.
9. Ascher-Svanum H., Stensland M.D., Kinon B.J., Tollefson G.D. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J. Psychopharmacol. 2005, 19:110-117.
10. Bartko G., Herczeg, Beksy M. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. J. Clin. Psychiatry 1987, 48:363-365.
11. Basson B.R., Kinon B.J., Taylor C.C., Sxymanski K.A., Gilmore J.A., Tollefson G.D. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol or riseridone. J. Clin. Psychiatry 2001, 62:231-238.
12. Bond, D.J., Kauer-Sant'Anna, M., et al., 2010. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). J. Affect. Disord. 124 (1-2), 108-117.
13. Bowie C.R., Reichenberg A., Patterson T.L., Heaton R.K., Harvey P.D. Determinants of real-world functional performance in schizophrenia subjects, correlations with cognition, functional capacity and symptoms. Am. J. Psychiatry 2006, 163:418-425.
14. Bowie C.R., Harvey P.D. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr. Dis. Treat. 2006, 2:531-536.
15. Buchanan R.W., Davis M., Goff D., et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 2005, 31:5-19.
16. Cassidy C.M., Ross N., Manchanda R., et al. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr. Bull. 2010, 36:1001-1008.
17. D'Agostino R.B., Ramachandran S.V., Pencina M.J., et al. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation 2008, 117:743-753.
18. Davidson M., Keefe R.S.E. Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr. Res. 1995, 17:123-129.
19. Delay J., Deniker P., Harl J.M. Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP). Ann. Med. Psychol. (Paris) 1952, 110:112-117.
20. Efron B., Tibshirani R. An Introduction to the Boostrap 1993, Chapman & Hall/CRC, Boca Raton, FL.
21. Fallmyr O., Repal A. Evaluering av GAF-skaring som del av minste bais datasett [Evaluation of GAF-rating as part of the minimum data set]. Tidsskr. Nor. Psykologforening 2002, 180:51-60.
22. Foussias G., Mann S., Zakzanis K.K., van Reekum R., Remington G. Motivational deficits as the central link to functioning in schizophrenia, a pilot study. Schizophr. Res. 2009, 115:333-337.
23. Greenberg G.A., Roesnheck R.A. Using the GAF as a national mental health outcome measure in the department of Veteran Affairs. Psychiatr. Serv. 2005, 56:420-426.
24. Hall R.C. Global assessment of functioning. A modified scale. Psychosomatics 1995, 36:267-275.
25. Heinrichs R.W., Ammari N., Miles A., McDermid V.S., Chopov B. Psychopathology and cognition in divergent functional outcomes in schizophrenia. Schizophr. Res. 2009, 109:46-51.
26. Jones P.B., Barnes T.R., Davis L. Randomized controlled trial of the effect on Quality of Life of second- vs. first-generation antipsychotic drugs in schizophrenia, cost utility of the Latest Antipsychotic Drugs in Schizophrenia Study (Cut-LASS 1). Arch. Gen. Psychiatry 2006, 63:1079-1087.
27. Jones S.H., Thornicroft G., Coffey M., et al. A brief mental health outcome scale, reliability and validity of the Global Assessment of Functioning (GAF). Br. J. Psychiatry 1995, 166:654-659.
28. Kapur S., Arenovich T., Agid O., Zipursky R., Lindborg S., Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am. J. Psychiatry 2005, 162:939-946.
29. Khin N.A., Chen Y.F., Yang Y., et al. Exploratory analysis of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J. Clin. Psychiatry 2012, 73:856-864.
30. Kinon B.J., Chen L., Ascher-Svanum H., et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr. Res. 2008, 102:230-240.
31. Leifker F.R., Bowie C.R., Harvey P.D. Determinants of everyday outcomes in schizophrenia, the influences of cognitive impairment, functional capacity, and symptoms. Schizophr. Res. 2009, 115(1):82-87.
32. Leucht S., Busch R., Hamann J., et al. Early onset hypothesis of antipsychotic drug action, a hypothesis tested, confirmed and extended. Biol. Psychiatry 2005, 57:1543-1549.
33. Leucht S., Corves C., Arbter D., et al. Second-generation versus first-generation antipsuchotic drugs for schizophrenia: a meta analysis. Lancet 2009, 373:31-41.
34. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
35. May P.R., van Putten T., Yale C. Predicting outcome of antipsychotic drug treatment from early response. Am. J. Psychiatry 1980, 137:1088-1089.
36. Meltzer H.Y., Alphs L., Green A.I., et al. Clozapine treatment for suicidality in schizophrenia, International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 2003, 60:82-91.
37. Meltzer H.Y., Cucchiaro J., Silva R., et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am. J. Psychiatry 2011, 168:957-967.
38. Murphy B.P., Chung Y.C., Park T.W., McGorry D. Pharmacological treatment of primary negative symptoms in schizophrenia, a systematic review. Schizophr. Res. 2006, 88:5-25.
39. Milev P., Ho B.C., Arndt S., et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia, a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 2005, 162:495-506.
40. Pedersen G., Hagtvet K.A., Karterud S. Generalizability studies of the Global Assessment of Functioning-Split Version. Compr. Psychiatry 2007, 48:88-94.
41. Perkins D.O., Gu H., Weiden P.J., et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episodes of schizophrenia, schizophreniform disorder, or schizoaffective disorder, a randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry 2008, 69:106-113.
42. Piersma H.L., Boes J.L. The GAF and psychotic outcome, a descriptive report. Community Ment. Health J. 1997, 33:35-41.
43. Potkin S.G., Saha A.R., Kujawa M.J., et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperisone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 2003, 60:681-690.
44. Rummel-kluge C., Komossa K., Schwarz S., et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 2010, 123(2):225-233.
45. Robinson D.G., Woerner M.G., McMeninam M., et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2004, 161:473-479.
46. Salvi G., Leese M., Slade M. Routine use of mental health outcome assessments, choosing the measure. Br. J. Psychiatry 2005, 186:146-152.
47. Schooler N.R. Relapse prevention and recvovery in the treatment of schizophrenia. J. Clin. Psychiatry 2006, 67(Suppl. 5):19-23.
48. Sevy S., Davidson M. The costs of cognitive impairment in schizophrenia. Schizophr. Res. 1995, 17:1-3.
49. Simpson G.M., Glick I.D., Weiden P.J., Romano S.J., Siu C.O. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2004, 161:1837-1847.
50. Simpson G.M., Weiden P., Pigott T., Murray S., Siu C.O., Romano S.J. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am. J. Psychiatry 2005, 162:1535-1538.
51. Stahl S.M., Malla A., Newcomer J.W., et al. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia, a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. J. Clin. Psychopharmacol. 2010, 30:425-429.
52. Stern R.G., Kahn R.S., Harvey P.D., et al. Early response to haloperidol treatment in chronic schizophrenia. Schizophr. Res. 1993, 10:165-171.
53. Vatnaland T., Vatnaland J., Friis S., et al. Are GAF scores reliable in routine clinical use?. Acta Psychiatr. Scand. 2007, 115:326-330.
54. Wittorf A., Wiedemann G., Buchkremer G., Klingberg S. Prediction of community outcome in schizophrenia one year after discharge from inpatient treatment. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258:48-58.